Top Stocks
Stock Comparison
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
NASDAQ:TGTX
TG Therapeutics Stock Analysis & Ratings
TGTX Stock Chart & Stats
Day’s Range$5.75 - $6.25
52-Week Range$5.51 - $41.00
Previous Close$6.1
Volume3.81M
Average Volume (3M)2.67M
Market Cap$872.39M
P/E Ratio-2.3
Beta2.24
Next EarningsAug 11, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$15.25
Smart Score5
EPS (TTM)-2.63
TG Therapeutics News
P/E Ratio Range
The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TGTX FAQ
What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest stock price was $5.51 and its highest was $41.00 in the past 12 months.
What is TG Therapeutics’s market cap?
TG Therapeutics’s market cap is $872.39M.
What is TG Therapeutics’s price target?
The average price target for TG Therapeutics is $15.25. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $23.00 ,the lowest forecast is $5.00. The average price target represents 152.48% Increase from the current price of $6.04.
The highest analyst price target is $23.00 ,the lowest forecast is $5.00. The average price target represents 152.48% Increase from the current price of $6.04.
What do analysts say about TG Therapeutics?
TG Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s upcoming earnings report date is Aug 11, 2022 which is in 83 days.
How were TG Therapeutics’s earnings last quarter?
Currently, no data Available
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TG Therapeutics have?
TG Therapeutics has 144,440,000 shares outstanding.
What happened to TG Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TG Therapeutics?
Among the largest hedge funds holding TG Therapeutics’s share is Maverick Capital ltd. It holds TG Therapeutics’s shares valued at 64M.
---
TG Therapeutics Stock Analysis
Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Price Target
$15.25
Moderate Buy▲(152.48% Upside)
Analyst Forecast
Moderate Buy
Average Price Target: $15.25
Blogger Sentiment
Neutral
TGTX Sentiment 50% Sector Average 70%
Hedge Fund Holdings
▼ Decreased
By 1.6M Shares Last Quarter.
Insider Transactions
N/A
Currently Not Enough Data Available
Retail Investors
Very Negative
Last 7 Days ▼ 0.9% Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish 50% Bearish 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.42%
12-Months-Change
Fundamentals
Return on Equity
-92.03%
Trailing 12-Months
Asset Growth
-39.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
TG Therapeutics
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.
---
Company
Price & Change
Follow
AbbVie
―
Johnson & Johnson
―
Gilead Sciences
―
Calithera Bio
―
Verastem
―
---